Primary pancreatic lymphoma

Primary pancreatic lymphoma (Primary Pancreatic Lymphoma, PPL) is a rare lymphoid neoplasm that arises in the pancreas and presents clinically as a dominant pancreatic mass, with or without regional lymph-node involvement, in the absence of predominant systemic lymphoma at diagnosis. Unlike ductal adenocarcinoma, the most common cause of a pancreatic mass in adults, PPL is potentially more sensitive to chemotherapy and immunotherapy and, if recognized early, may have a significantly better outcome. Correct distinction is therefore crucial because it avoids unnecessary pancreatic resections and rapidly directs the patient to specific hematologic-oncologic treatment.

In most cases, PPL corresponds to diffuse large B-cell lymphoma, whereas indolent or non-B-cell subtypes are less common. Its clinical presentation may mimic pancreatic carcinoma, with epigastric pain, weight loss and sometimes obstructive jaundice when the lesion is in the pancreatic head. Certain features may be suggestive: a bulky mass with relatively limited pancreatic-duct dilatation, lymphoma-type systemic symptoms in a minority of patients, and a metabolic pattern on 18F-FDG PET that often shows markedly increased uptake.

The diagnostic pathway must culminate in histologic confirmation, preferably using a specimen adequate for immunohistochemistry and, when necessary, molecular studies. Endoscopic ultrasonography with biopsy (core biopsy or cell-block sampling) is central because it permits lymphoma classification and prompt initiation of treatment. Once the diagnosis has been established, staging and prognostic stratification follow the principles for aggressive lymphomas, with particular attention to bone marrow, PET/CT and clinical parameters used in the IPI.

The epidemiology of primary pancreatic lymphoma is defined by its rarity. It accounts for a small proportion of pancreatic neoplasms and a minority of extranodal lymphomas. In practical terms, much of the evidence comes from retrospective series, registries and reviews with nonuniform inclusion criteria; this contributes to variability in estimates and requires caution when interpreting incidence and outcomes.

Most patients are adults, often middle-aged or older, and the lesion is most frequently located in the pancreatic head, which explains obstructive jaundice in some cases. The most common histologic subtype is diffuse large B-cell lymphoma, whereas other variants, such as T-cell, MALT or follicular lymphomas with a dominant pancreatic presentation, are much less frequent. In non-DLBCL cases, assessment must be even more rigorous to distinguish true primary pancreatic disease from secondary involvement by systemic lymphoma.

The etiologic causes of PPL are not unequivocally defined, and no exposure has been documented as a necessary and sufficient direct cause. In practice, the disease is considered to result from lymphoid transformation at an extranodal site, with incompletely understood immunologic and microenvironmental contributions.

In the absence of a demonstrated etiology, risk factors are discussed mainly as conditions that increase the likelihood of non-Hodgkin lymphoma or facilitate its emergence at extranodal sites. These include states of immunodeficiency (iatrogenic or acquired), certain infections and chronic immune dysfunction, although none has a specific and consistent association with the pancreas. Clinically, these conditions are insufficient to predict PPL but may heighten suspicion when a pancreatic mass has features atypical for adenocarcinoma and signs compatible with a lymphoid disorder coexist.

In summary, PPL is rare, predominantly B-cell and most often DLBCL. Its etiology is undefined, whereas risk factors are those generally associated with lymphoma and impaired immune surveillance, without a predictive profile specific to the pancreatic site.

For primary pancreatic lymphoma, there are no screening programs or population surveillance strategies are available because the disease is too rare and no noninvasive test has sufficient accuracy. Early identification therefore occurs through a diagnostic pathway triggered by symptoms or incidental imaging findings.

In practice, ultrasonography or CT performed for abdominal pain, jaundice or weight loss may reveal a pancreatic mass. The priority in this setting is not PPL “screening” but a rapid differential diagnosis among adenocarcinoma, neuroendocrine neoplasms, focal pancreatitis, metastases and lymphoma. Certain radiologic patterns may suggest lymphoid origin and prompt early endoscopic ultrasound-guided biopsy, reducing the risk of unnecessary surgery.

A separate issue concerns patients with known lymphoma: in these cases, pancreatic findings may represent secondary involvement rather than a primary tumor. Surveillance follows protocols for the underlying lymphoma, and pancreatic assessment is driven by symptoms or PET/CT findings, with the aim of defining active disease and obtaining tissue when histologic diagnosis or reassessment for transformation would change treatment.

Overall, the rational approach is guided by symptoms and imaging, with a low threshold for tissue acquisition when a pancreatic mass is atypical for adenocarcinoma and recognition of lymphoma would radically change the therapeutic strategy.

The biology of primary pancreatic lymphoma reflects that of extranodal lymphomas, with a predominance of aggressive B-cell forms. The pancreas is not classically rich in organized lymphoid tissue, but it contains resident immune cells and may host reactive infiltrates in inflammatory settings. In this context, a B-cell clone may acquire genetic alterations conferring proliferative, survival and invasive advantages, culminating in a rapidly growing lymphoma phenotype. The rarity of this site suggests that local microenvironmental factors and inflammatory signals may have a permissive role, although no single causal model has been established.

In the most common subtype, DLBCL, pathogenesis involves dysregulation of B-cell differentiation programs and alterations in pathways controlling proliferation and the response to genomic stress. Modern classification of large B-cell lymphomas integrates morphology, immunophenotype and, when available, genetic data because biologically and prognostically distinct entities may share a “DLBCL-like” phenotype. This precision is also relevant to pancreatic forms because classification influences treatment intensity, indications for central nervous system prophylaxis in selected cases and salvage strategies.

Biological features relevant to clinical management

• Predominance of DLBCL as the histologic type, requiring definition of immunophenotype and, when indicated, biologic subgroups with therapeutic implications.
• An adequate specimen is important for distinguishing DLBCL from other aggressive B-cell entities and from transformed indolent lymphomas.
• Clinical relevance of functional staging with PET/CT to define disease burden and response, consistent with the highly metabolic biology of aggressive forms.

Histologically, PPL may appear as a diffuse infiltrate of large atypical cells replacing the pancreatic parenchyma, sometimes with areas of necrosis. Immunohistochemistry is essential to confirm B-cell lineage, for example CD20 and other B-cell markers, and to define expression patterns useful for classification and prognosis, including proliferative index and markers informing biological profile. When the specimen is obtained by fine-needle aspiration, cell-block preparation and core biopsy improve subtype reliability by preserving architecture and permitting more complete panels.

The histologic differential diagnosis includes poorly differentiated adenocarcinoma, neuroendocrine neoplasms, autoimmune pancreatitis and metastases, as well as rare sarcomas. An integrated pathologic-radiologic approach is therefore decisive: classification is not an academic exercise but the prerequisite for selecting potentially curative systemic therapy and avoiding disproportionate surgical treatment.

The clinical manifestations of primary pancreatic lymphoma often overlap those of other pancreatic masses. The most common symptom is epigastric pain or upper abdominal pain, sometimes radiating to the back and often accompanied by weight loss and reduced appetite. When the lesion involves the pancreatic head, obstructive jaundice may occur because of compression or infiltration of the bile ducts, with pruritus, dark urine and abnormal cholestatic indices.

Unlike adenocarcinoma, marked dilatation of the main pancreatic duct may be less pronounced relative to mass size because lymphoma tends to grow as an infiltrate and compress rather than induce a desmoplastic reaction. This finding is not reliable in isolation and must be interpreted in the overall context. A minority of patients may have lymphoma-type systemic symptoms such as fever, night sweats and fatigue, but their absence does not exclude PPL.

Physical findings may be limited in early stages. Advanced disease may cause jaundice, hepatomegaly, right upper-quadrant tenderness or signs of general deterioration. The absence of specific findings makes a diagnostic pathway prioritizing tissue acquisition essential.

Clinical presentations that most often lead to pancreatic imaging

• Persistent epigastric pain with weight loss and loss of appetite.
• Obstructive jaundice with biochemical cholestasis, especially with a mass in the pancreatic head.
• An incidental pancreatic mass on CT or MRI performed for another indication.
• Systemic signs compatible with lymphoma in the presence of a pancreatic lesion.
• Radiologic findings atypical for adenocarcinoma that require histologic classification.

Overall, clinical findings alone cannot reliably distinguish PPL from adenocarcinoma. The strategy makes the difference: when a pancreatic mass may be lymphomatous, priority should be given to complete histologic diagnosis before any definitive therapeutic decision.

Suspicion arises from imaging performed for symptoms or incidentally. The diagnostic sequence must rapidly achieve three objectives: confirm the lymphomatous nature of the lesion, classify the subtype according to current classifications and complete staging to distinguish true primary pancreatic disease from secondary involvement by systemic lymphoma.

First-line investigations include CT or MRI to define location, size, vascular relationships, biliary involvement and possible nodal disease. CT also provides an initial assessment of target organs, particularly the liver and abdominal lymph nodes. 18F-FDG PET/CT is highly useful in aggressive lymphomas because it improves assessment of disease extent and provides a functional baseline for treatment response.

The decisive step is tissue acquisition. Endoscopic ultrasonography with fine-needle aspiration, preferably combined with core biopsy or an adequate cell block, is often the technique of choice because it provides representative samples at low risk and permits complete immunohistochemical panels. The specimen must be handled through a lymphoma-specific pathway, including extended immunohistochemistry and, when necessary, flow cytometry and genetic studies. This is essential to distinguish DLBCL from other entities and identify transformation from an indolent lymphoma, which changes prognosis and treatment.

After histologic diagnosis, assessment proceeds with systemic staging: PET/CT, complete blood count and chemistry, LDH assessment, possible bone-marrow biopsy according to the clinical context and recommendations, and prognostic evaluation with the IPI in DLBCL. Primary pancreatic origin is established clinically and radiologically: the pancreas is the dominant site, there is no diffuse nodal disease and no massive involvement of extrapancreatic organs at diagnosis.

According to guidelines for aggressive lymphoma management, reliable histologic classification and complete staging are required to establish the diagnosis and correctly plan treatment, avoiding diagnoses based on imaging or inadequate cytology:

Essential elements for a clinically useful diagnosis

• High-quality imaging (CT or MRI) defining vascular relationships and assessing lymph nodes and liver.
• An adequate specimen for lymphoma classification, preferably obtained by core biopsy or a cell block suitable for complete panels.
• Immunohistochemistry and, when indicated, flow cytometry and genetic analyses for current classification.
• PET/CT for functional staging and response baseline in FDG-avid subtypes.
• Clinical and laboratory prognostic assessment, including LDH and parameters used in the IPI for DLBCL.

In summary, PPL diagnosis is imaging-guided but pathology-defined: without an adequate specimen, a potentially highly chemosensitive disease may be treated as carcinoma, with major consequences for prognosis and therapeutic appropriateness.

Staging of primary pancreatic lymphoma follows the principles used for non-Hodgkin lymphomas, with reference to Ann Arbor staging in its modern application to extranodal lymphoma and, in contemporary clinical practice, integration of PET/CT. Because the pancreatic site is extranodal, stage description should specify nodal and extranodal involvement and any distant dissemination. In DLBCL, staging is complemented by prognostic stratification with the IPI, which remains clinically relevant in extranodal presentations.

In practice, the distinction between disease confined to the pancreas, with or without regional lymph nodes, and disseminated disease influences strategy. PET/CT is decisive for defining extent, selecting the number of cycles and evaluating metabolic response, an important prognostic factor in aggressive lymphomas.

Clinical staging of lymphoma involving the pancreas (Ann Arbor with extranodal extension)

• Stage I: involvement of a single extranodal site, the pancreas (E), without distant nodal involvement.
• Stage II: pancreatic involvement (E) with regional lymph nodes on the same side of the diaphragm.
• Stage III: nodal involvement on both sides of the diaphragm, with or without pancreatic extranodal disease (E).
• Stage IV: diffuse or disseminated involvement of one or more distant extranodal organs beyond the pancreas, such as bone marrow or liver with a disseminated pattern.

The prognosis of PPL is generally more favorable than that of pancreatic adenocarcinoma but depends critically on subtype, stage and treatment response. In DLBCL, major determinants include IPI, advanced disease, LDH levels, performance status and early metabolic response to treatment. The possibility of complete remission with standard immunochemotherapy is central and makes prompt diagnosis the main modifiable factor affecting outcome.

In indolent subtypes or transformed disease, prognosis depends on the underlying biology and the ability to control both the aggressive component and any late recurrences. In all cases, prognostic interpretation must be integrated into a multidisciplinary context that also considers comorbidities, hepatic and biliary function, and the need for drainage procedures when jaundice interferes with treatment initiation.

Treatment of primary pancreatic lymphoma is mainly systemic and follows strategies for aggressive lymphomas, aiming to achieve complete remission while avoiding unnecessary major surgery. In the most common form, DLBCL, the therapeutic backbone is anti-CD20 immunochemotherapy combined with multidrug chemotherapy, tailored to age, comorbidities and biological risk. Management should be prompt because treatment delay may worsen conditions related to jaundice, cholangitis or nutritional deterioration.

In patients presenting with obstructive jaundice, endoscopic biliary decompression when necessary is often a decisive practical step, permitting safe treatment initiation and reducing infectious complications. This intervention is not curative for lymphoma but may be essential for treatment feasibility, particularly when marked cholestasis limits the use of hepatically metabolized drugs.

The role of surgery is limited. Pancreatic resection is not standard treatment for PPL and generally reflects an erroneous preoperative diagnosis of carcinoma. In selected cases, however, it may be performed for complications or when an adequate tissue diagnosis cannot be obtained by less invasive methods. The preferred strategy remains obtaining tissue by endoscopic ultrasonography and initiating systemic therapy.

Radiotherapy may be discussed in selected scenarios as consolidation for localized disease or for residual local control, but it is not a universal cornerstone and should be considered case by case according to response, site and the risk of toxicity to critical organs. In refractory or relapsed disease, modern DLBCL principles apply, including salvage therapies, bispecific antibodies and, in selected patients, cellular therapies, with decisions made at experienced centers.

Treatment objectives according to the clinical setting

• Localized disease: anti-CD20 immunochemotherapy, with PET/CT reassessment and consideration of selected consolidation according to response and risk.
• Advanced disease: systemic immunochemotherapy with close monitoring and management of biliary and nutritional complications.
• Refractory or relapsed disease: salvage strategies according to DLBCL guidelines, including innovative options at specialized centers.
• Supportive care: biliary drainage when indicated, infection prophylaxis and management of metabolic and infectious emergencies.

In summary, treatment of PPL is time-sensitive: the most important decision is to recognize its lymphomatous nature and initiate appropriate systemic therapy, integrating supportive procedures that make treatment feasible and safe.

Follow-up after treatment for primary pancreatic lymphoma follows the principles used for aggressive lymphomas and integrates clinical assessment, laboratory tests and imaging according to risk and response. In DLBCL, PET/CT is central to end-of-treatment response assessment and, in selected settings, interim reassessment when the result would change management.

Clinical surveillance should focus on recurrence of abdominal pain, weight loss, signs of cholestasis, persistent fever or systemic symptoms. Laboratory assessment includes complete blood count and chemistry with particular attention to liver function, especially in patients who presented with jaundice or underwent biliary procedures. Structural imaging (CT or MRI) is used selectively when suspicious symptoms or clinical findings emerge.

An important component of follow-up is monitoring late treatment toxicities, including anthracycline-related cardiac complications, neuropathy and infectious risk, according to established lymphoma pathways. Patients who required biliary drains or stents need coordinated gastroenterologic management to prevent cholangitis and maintain patency until lymphomatous compression has completely resolved.

Overall, follow-up aims to identify clinically relevant relapse early, manage late effects, and preserve quality of life and hepatobiliary function through continuity of care between hematology and gastroenterology.

Long-term quality-of-life considerations in primary pancreatic lymphoma depend on the balance between disease control and treatment sequelae. Patients achieving complete remission may have a good quality of life, although some develop persistent fatigue, reduced physical performance and concern about relapse, especially during the first years after treatment.

Initial jaundice and biliary procedures may prolong convalescence, requiring follow-up and potentially affecting diet and sleep. In some patients, the experience of a diagnosis initially suspected to be pancreatic carcinoma and subsequently reclassified as lymphoma may create a distinctive psychological burden, oscillating between relative prognostic relief and uncertainty related to intensive treatment and follow-up.

Sequelae of systemic treatment, including peripheral neuropathy, transient susceptibility to infection and possible late cardiac effects, may affect work and independence. Follow-up oriented toward functional rehabilitation, adapted physical activity and management of persistent symptoms improves recovery and social reintegration.

Psycho-oncologic support and structured communication regarding warning signs, the rationale for follow-up and toxicity-prevention strategies help reduce fear of relapse and improve adherence. Overall, long-term quality of life is optimized by an integrated pathway involving hematology, gastroenterology and internal medicine, with attention to overall well-being in addition to remission.

Complications of primary pancreatic lymphoma arise from the mass and its effects on the pancreaticobiliary region, as well as from treatment. Among local complications, obstructive jaundice is particularly important because it may be complicated by cholangitis and delay chemotherapy if not managed promptly. Duodenal compression or local infiltration may cause nausea, vomiting and malnutrition, worsening performance status.

Systemic therapy may be complicated by myelosuppression, infections and, with anthracycline-containing regimens, cumulative cardiotoxicity. In patients with jaundice, pharmacologic management requires particular care to avoid toxicity and adjust doses when indicated. Endoscopic biliary procedures may be complicated by post-ERCP pancreatitis, bleeding or infection, requiring close coordination among teams.

• Biliary complications: cholangitis, stent dysfunction and persistent jaundice requiring repeat endoscopic procedures.
• Treatment-related infectious and hematologic complications: febrile neutropenia, opportunistic infections, need for prophylaxis and growth-factor support when appropriate.
• Organ toxicity: anthracycline cardiotoxicity, neuropathy from specific agents and hepatotoxicity in the setting of cholestasis.

Prevention and management of complications rely on prompt biliary decompression when necessary, rapid initiation of disease-specific therapy after tissue diagnosis, close laboratory monitoring during cycles and multidisciplinary care. Well-structured follow-up reduces missed clinically late relapses and improves management of sequelae.